

First Commercial Use of Jointechlabs' Mini-Stem System in Italy, Greece, and Cyprus

Following CE-Mark approval, Jointechlabs' Mini-Stem Microfat system was successfully used in orthopedic and aesthetic procedures in Italy, Greece, and Cyprus.

BRANDON, FL, UNITED STATES, February 25, 2025 /EINPresswire.com/ -- [Jointechlabs](#), Inc., a US-based regenerative medicine device and therapeutics company, proudly announced the first successful use of its groundbreaking medical device, [Mini-Stem System](#)[®], in Italy, Greece,

and Cyprus. This milestone represents a significant advancement in regenerative medicine healthcare in the European Union. Doctors, hospitals, clinics, and patients can now access leading-edge technology to help avoid surgery for orthopedic patients with joint pain.



We worked very hard to reach this moment. The successful use of Mini-Stem System in Italy is a key marker for Jointechlabs, but also for improving orthopedic patient outcomes worldwide."

*Dr. Nathan Katz, CEO
Jointechlabs, Inc.*

Additionally, Mini-Stem can provide a natural filler for aesthetic indications.

Mini-Stem System produces the purest regenerative microfat from a patient's own body. Microfat procedures can be done in a local clinic, under local anesthesia, in as little as one hour. The provider injects the resultant microfat into the painful area in orthopedic situations. In aesthetic treatments, the provider uses microfat as a natural dermatologic filler.

□ Orthopedic Use



The first Mini-Stem orthopedic patient in Italy underwent a procedure under the care of Dr. Marco Spoliti, a leading orthopedic and trauma surgeon. This marked a pivotal moment in the expansion of advanced medical treatments in the region.

□ A Unique System

Mini-Stem System produces the purest microfat of any available device. And it is the only system in the world that goes beyond microfat and isolates and produces Stromal Vascular Fraction (SVF). SVF is an advanced regenerative substance which eager doctors and patients can now use.

Mini-Stem underwent rigorous testing and has also [received CE-Mark approval](#), ensuring its safety and efficacy within EU healthcare systems. This achievement paves the way for broader adoption within the EU community. A sister device is well established in the US.

□ Aesthetic Use

Microfat grafting offers benefits because it uses fat from the patient's own body. Therefore the results tend to look more natural than those achieved with synthetic fillers. The transferred micronized fat cells contain the stromal cells that potentially will last years. By comparison, synthetic fillers may require frequent touch-ups.

Prominent physicians including Dr. Francesco Calvani, a maxillofacial surgeon, and renowned plastic surgeons Dr. Neophytos Demetriades and Dr. Angeles Karatzias performed aesthetic procedures in Italy, Greece, and Cyprus.

Nishit Pancholi, MD, COO of Jointechlabs, said "With the successful introduction of Mini-Stem System, Jointechlabs continues its mission of expanding access to regenerative medicine technologies worldwide. With our EU-based development and distribution partners, we are working with healthcare providers across the EU to train medical professionals and ensure the successful integration of Mini-Stem System for both orthopedic and aesthetic indications."

□ About Jointechlabs



www.jointechlabs.com



Dr. Neophytos Demetriades, Dr. Marco Spoliti, and Dr. Francesco Calvani

Privately-held Jointechlabs is an emerging worldwide leader in point-of-care regenerative medicine. Jointechlabs enables healthcare practitioners and hospitals to provide safe, cost-effective, non-surgical regenerative medicine therapies. These therapies can be done at the point-of-care without change in infrastructure.

FDA-cleared MiniTC® for the US market is a stand-alone device for processing autologous fat into regenerative-cell-rich microfat for a variety of orthopedic, aesthetic, wound healing, and reconstructive surgery applications. Outside the US, CE-Mark-approved Mini-Stem System® prepares microfat and also extracts Stromal Vascular Fraction.

Pipeline products include stem-cell therapeutics such as 3D Bioprinted wound repair and injectable stem cell scaffolds.

More information: www.jointechlabs.com

Full story: <https://jointechlabs.com/first-commercial-use-of-jointechlabs-mini-stem-system-in-italy-greece-and-cyprus/>

Media Relations

Jointechlabs, Inc.

+1 800-217-0491

info@jointechlabs.com

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

[Instagram](#)

[YouTube](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/788173215>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.